Atrium Therapeutics Inc (RNA)

May 03, 2026

RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo

May 03, 2026

Apr 29, 2026

Fierce Biotech Fundraising Tracker '26: Vivacta snags $50M+ series A; Coultreon reels in $125M - Fierce Biotech

Apr 29, 2026

Apr 28, 2026

Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN

Apr 28, 2026

Apr 27, 2026

BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan

Apr 27, 2026

Apr 27, 2026

Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews

Apr 27, 2026

Apr 24, 2026

Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News

Apr 24, 2026

Apr 23, 2026

BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire

Apr 23, 2026

Apr 23, 2026

RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 23, 2026

Apr 23, 2026

RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan

Apr 22, 2026

Apr 22, 2026

[Form 4] Atrium Therapeutics, Inc. Insider Trading Activity - Stock Titan

Apr 22, 2026

Apr 22, 2026

Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan

Apr 22, 2026

Apr 22, 2026

Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option - Stock Titan

Apr 22, 2026

Apr 22, 2026

Atrium Therapeutics (RNA) CSO awarded 30,000 RSUs and 60,000 options - Stock Titan

Apr 22, 2026

Apr 22, 2026

Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan

Apr 22, 2026

Apr 22, 2026

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm

Apr 22, 2026

Apr 21, 2026

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network

Apr 21, 2026

Apr 20, 2026

Omdia: India’s smartphone shipments fell 5% in 1Q26 amid channel caution and pricing pressures - Weekly Voice

Apr 20, 2026

Apr 20, 2026

Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan

Apr 20, 2026

Apr 20, 2026

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Grand Junction Daily Sentinel

Apr 20, 2026

Apr 18, 2026

Form S-8Securities to be offered to employees in employee benefit plans - ADVFN

Apr 18, 2026

Apr 14, 2026

Atrium Therapeutics Inc - Reuters

Apr 14, 2026

Apr 09, 2026

Atrium Therapeutics Inc. Live Share Prices and Trades. RNA.US Live Streaming Share Prices. - London South East

Apr 09, 2026

Apr 09, 2026

Is Atrium Therapeutics (RNA) Stock Declining | Price at $13.72, Up 0.15%Reversal Setup - Newser

Apr 09, 2026

Apr 08, 2026

T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan

Apr 08, 2026

Apr 06, 2026

Is Atrium Therapeutics (RNA) Stock Worth Buying Now | Price at $13.77, Up 2.46%Popular Trader Picks - Newser

Apr 06, 2026

Apr 02, 2026

RNA Rallies on Expansion News - Newser

Apr 02, 2026

Apr 01, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Apr 01, 2026

Mar 31, 2026

Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart - Capital.com

Mar 31, 2026

Mar 31, 2026

Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com

Mar 31, 2026

Mar 30, 2026

RNA PE Ratio & Valuation, Is RNA Overvalued - Intellectia AI

Mar 30, 2026

Mar 25, 2026

Mast Multialternative Strategy Fund's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus

Mar 25, 2026

Mar 23, 2026

Atrium Therapeutics, Inc. (RNA): Investor Outlook On A Potential 90% Upside - DirectorsTalk Interviews

Mar 23, 2026

Mar 22, 2026

Atrium Therapeutics, Inc.(NasdaqGS:RNA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Mar 22, 2026

Mar 21, 2026

RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026

Mar 19, 2026

Stephanie Kenney Net Worth (2026) - GuruFocus

Mar 19, 2026

Mar 19, 2026

Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice

Mar 19, 2026

Mar 19, 2026

Rocio Martin Hoyos Net Worth (2026) - GuruFocus

Mar 19, 2026

Mar 19, 2026

Brendan R. Winslow Net Worth (2026) - gurufocus.com

Mar 19, 2026

Mar 18, 2026

Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World

Mar 18, 2026

Mar 11, 2026

Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com

Mar 11, 2026

Mar 06, 2026

Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights

Mar 06, 2026

Mar 06, 2026

Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au

Mar 06, 2026

Mar 06, 2026

Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech

Mar 06, 2026

Mar 06, 2026

Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media

Mar 06, 2026

Mar 04, 2026

Atrium Therapeutics Inc Share Price USD0.001 - Hargreaves Lansdown

Mar 04, 2026

Mar 04, 2026

Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies - BioXconomy

Mar 04, 2026